Seaport Therapeutics
Seaport Therapeutics is hiring a Director, Analytical Research and Development, CMC to lead analytical activities supporting development of its neuropsychiatric drug candidates based on the proprietary Glyph platform. The role is based in Boston and focuses on phase-appropriate analytical strategy for drug substance and drug product in early clinical development.
Seaport Therapeutics is a biotechnology company developing novel neuropsychiatric medicines. The company applies its Glyph platform to advance potentially best-in-class therapeutics designed to improve efficacy and tolerability for patients with depression, anxiety, and other neuropsychiatric disorders.
Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
2 weeks ago
Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Jan 5, 2026
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
3 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Seaport Therapeutics.
Analytical Lead
Neurocrine Biosciences
Principal Scientist
Denali Therapeutics
Associate Director of CMC Analytical Development
Syncromune®
Associate Director/Director of CMC Analytical Development
Syncromune®
Sr. Scientist, Analytical Chemistry, CMC
Neurocrine Biosciences
Senior Scientist, Analytical Development, Biologics CMC
Exelixis